GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » Cash Flow from Operations

SIBN (SI-BONE) Cash Flow from Operations : $-9.8 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is SI-BONE Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2025, SI-BONE's Net Income From Continuing Operations was $-6.5 Mil. Its Depreciation, Depletion and Amortization was $1.3 Mil. Its Change In Working Capital was $-6.2 Mil. Its cash flow from deferred tax was $0.0 Mil. Its Cash from Discontinued Operating Activities was $0.0 Mil. Its Asset Impairment Charge was $0.0 Mil. Its Stock Based Compensation was $6.7 Mil. And its Cash Flow from Others was $-0.1 Mil. In all, SI-BONE's Cash Flow from Operations for the three months ended in Mar. 2025 was $-4.9 Mil.


SI-BONE Cash Flow from Operations Historical Data

The historical data trend for SI-BONE's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE Cash Flow from Operations Chart

SI-BONE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only -30.66 -39.53 -41.66 -18.71 -12.43

SI-BONE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.57 -6.33 0.30 1.18 -4.91

SI-BONE Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

SI-BONE's Cash Flow from Operations for the fiscal year that ended in Dec. 2024 is calculated as:

SI-BONE's Cash Flow from Operations for the quarter that ended in Mar. 2025 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SI-BONE  (NAS:SIBN) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

SI-BONE's net income from continuing operations for the three months ended in Mar. 2025 was $-6.5 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

SI-BONE's depreciation, depletion and amortization for the three months ended in Mar. 2025 was $1.3 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

SI-BONE's change in working capital for the three months ended in Mar. 2025 was $-6.2 Mil. It means SI-BONE's working capital declined by $6.2 Mil from Dec. 2024 to Mar. 2025 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

SI-BONE's cash flow from deferred tax for the three months ended in Mar. 2025 was $0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

SI-BONE's cash from discontinued operating Activities for the three months ended in Mar. 2025 was $0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

SI-BONE's asset impairment charge for the three months ended in Mar. 2025 was $0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

SI-BONE's stock based compensation for the three months ended in Mar. 2025 was $6.7 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

SI-BONE's cash flow from others for the three months ended in Mar. 2025 was $-0.1 Mil.


SI-BONE Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of SI-BONE's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


SI-BONE Business Description

Traded in Other Exchanges
N/A
Address
471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Executives
Anshul Maheshwari officer: Chief Financial Officer 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis officer: Chief Financial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Anthony J Recupero officer: Chief Commercial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael A Pisetsky officer: GC & Chief Compliance Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn director, officer: Chairman, President & CEO C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Davis Timothy E Jr director 5677 AIRLINE ROAD, ARLINGTON TN 38002
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh director 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Skyline Venture Partners V Lp 10 percent owner 525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling officer: CMO and VP, Medical Affairs C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby officer: Chief Technology Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451